About
C4 Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 9 2026
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Mar 25 2026
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Feb 26 2026
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Feb 23 2026
C4 Therapeutics to Participate in Upcoming March Conferences
Feb 23 2026
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
Recent Videos

09 April 26. Biotech Stock News. Daily Recap #English #Shorts $XBI #trading #biotechnews #dailynews
Apr 09, 2026

09 abril 26. Noticias acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI #bio
Apr 09, 2026

CCCC STOCK : POTENTIAL BOUNCEBACK | C4 THERAPEUTICS STOCK
Mar 31, 2026

Cómo comprar acciones de C4 Therapeutics Inc (CCCC)
Feb 25, 2026
Google Übersetzer